Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. The Company is leveraging its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from its platform in clinical studies, QINLOCK is Deciphera's FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Canada and Australia. Show more

Location: 200 Smith St, Massachusetts, 02451-0099, United States | Website: www.deciphera.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing

Market Cap

0.00

52 Wk Range

$N/A - $N/A

Previous Close

$25.59

Open

$25.59

Volume

600

Day Range

$25.59 - $25.59

Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Insider Ownership

28.48%

Institutional Own.

72.03%

Qtr Updated

06/30/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Qinlock (ripretinib) (KIT & PDGFRA inhibitor) Details GIST (Gastrointestinal stromal tumors) (fourth-line)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vimseltinib (DCC-3014) (CSF1R inhibitor) Details Tenosynovial Giant Cell Tumors, Cancer	NDA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Qinlock (Ripretinib) Details Gastrointestinal stromal tumors	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vimseltinib (DCC-3014) (CSF1R inhibitor) Details Cancer, Tenosynovial Giant Cell Tumors	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DCC-3116 (Inhibitor of ULK) + trametinib, sotorasib & binimetin Details Solid tumor/s, Cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DCC-3116 (Inhibitor of ULK)+encorafenib & cetuximab Details Solid tumor/s, Colorectal cancer , Cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DCC-3116 (Inhibitor of ULK)+Qinlock Details Solid tumor/s, Gastrointestinal stromal tumors	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rebastinib (TIE2 inhibitor) + Paclitaxel Details Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.